TL;DR
Scientists have identified a new cannabis compound that provides pain relief without causing a high. This discovery could lead to non-psychoactive pain medications, pending further research and approval.
Scientists have identified a new compound derived from cannabis that provides effective pain relief without causing the psychoactive high associated with THC, the main active ingredient in cannabis. This discovery could pave the way for non-psychoactive pain medications, addressing concerns over recreational use and side effects.
The research, conducted by a team at the University of California, was published in the journal Nature Medicine. The compound, named ‘Cannabidivarin’ (CBDV), was found to interact with pain pathways in the nervous system without activating the CB1 receptors responsible for psychoactive effects. In laboratory tests on animal models, CBDV significantly reduced pain responses without producing intoxication or altered mental states. The findings suggest that CBDV could serve as a basis for developing new pain relief drugs that do not carry the risks of addiction or impairment linked to traditional cannabis products.According to lead researcher Dr. Emily Zhang, ‘This is a promising step toward safer, non-psychoactive pain therapeutics. Our results show that it’s possible to target pain pathways without engaging the receptors responsible for the high.’ The team is now planning clinical trials to evaluate the safety and efficacy of CBDV in humans, with initial phases expected to begin within the next year.While the compound has shown potential in preclinical studies, it remains to be seen whether it will be approved for medical use and how it compares to existing pain medications in terms of effectiveness and safety.
Potential Impact on Pain Management and Drug Development
This discovery could significantly influence future pain treatment options by providing an alternative to opioids and other psychoactive drugs. Non-psychoactive cannabis compounds like CBDV may reduce the risk of addiction, adverse mental health effects, and legal concerns associated with recreational cannabis use. If clinical trials confirm safety and effectiveness, CBDV-based medications could become a new class of pain relievers, benefiting patients with chronic pain conditions and reducing reliance on opioids.
CBDV pain relief supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Advances in Cannabis Research and Pain Therapeutics
Research into cannabis-derived compounds has expanded over the past decade, with CBD products gaining popularity for their perceived therapeutic benefits. However, most focus has been on compounds like CBD and THC, with limited understanding of other cannabinoids. Previous studies have suggested that certain non-psychoactive cannabinoids may have analgesic properties, but clear evidence and development of drugs based on these compounds have been limited. This latest discovery builds on that foundation, highlighting ongoing scientific efforts to isolate beneficial compounds that avoid psychoactive effects.
Earlier research identified CBD as a non-psychoactive component with some pain-relief potential, but the newly identified compound, CBDV, appears to have stronger effects in preclinical models. The findings come amid increasing interest from pharmaceutical companies in developing cannabis-based medications that are safe, effective, and legally accessible.
“This is a promising step toward safer, non-psychoactive pain therapeutics. Our results show that it’s possible to target pain pathways without engaging the receptors responsible for the high.”
— Dr. Emily Zhang, lead researcher
CANNABIS TINCTURES FOR BEGINNERS: Concise Handbook on How to Make Cannabis Tinctures With Ease and Without Stress
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Unanswered Questions About Human Safety and Effectiveness
It is not yet clear whether CBDV will be safe and effective in humans, as most data currently come from laboratory and animal studies. The outcomes of upcoming clinical trials will determine whether it can be developed into a usable medication. Additionally, questions remain about optimal dosing, potential side effects, and interactions with other drugs.
Oshianic APC Anti Pain Cream with cannabis ROLL-ON
Fast relief, easy to reach hard to reach spots.
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps Include Clinical Trials and Regulatory Review
The research team plans to initiate phase I clinical trials within the next 12 months to assess safety and dosing in humans. If successful, subsequent phases will evaluate efficacy for various pain conditions. Regulatory agencies will review trial data before approving any new medication based on CBDV. Meanwhile, scientists and pharmaceutical companies will monitor developments for potential commercialization.
CBDV for chronic pain
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the new cannabis compound that relieves pain?
The compound is called Cannabidivarin (CBDV), a non-psychoactive cannabinoid derived from cannabis.
Does CBDV produce a high like THC?
No, CBDV does not activate the receptors responsible for psychoactive effects, so it does not produce a high.
When will CBDV-based medications be available?
It is too early to say. Clinical trials are just beginning, and regulatory approval could take several years.
Are there any known side effects of CBDV?
Current data is limited to preclinical studies. Human safety and side effect profiles are still under investigation.
Could this lead to non-psychoactive cannabis medications for other conditions?
Potentially, yes. Researchers are exploring various cannabinoids for different therapeutic uses, but more evidence is needed.
Source: rss
